239 related articles for article (PubMed ID: 19169236)
1. Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality?
Dodson PM
Eye (Lond); 2009 May; 23(5):997-1003. PubMed ID: 19169236
[TBL] [Abstract][Full Text] [Related]
2. Diabetic retinopathy: treatment and prevention.
Dodson PM
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S9-S11. PubMed ID: 17935059
[TBL] [Abstract][Full Text] [Related]
3. Fenofibrate - a potential systemic treatment for diabetic retinopathy?
Wong TY; Simó R; Mitchell P
Am J Ophthalmol; 2012 Jul; 154(1):6-12. PubMed ID: 22709833
[TBL] [Abstract][Full Text] [Related]
4. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.
Keech AC; Mitchell P; Summanen PA; O'Day J; Davis TM; Moffitt MS; Taskinen MR; Simes RJ; Tse D; Williamson E; Merrifield A; Laatikainen LT; d'Emden MC; Crimet DC; O'Connell RL; Colman PG;
Lancet; 2007 Nov; 370(9600):1687-97. PubMed ID: 17988728
[TBL] [Abstract][Full Text] [Related]
5. Lipids, lipid-lowering therapy and diabetes complications.
Valensi P; Picard S
Diabetes Metab; 2011 Feb; 37(1):15-24. PubMed ID: 21126902
[TBL] [Abstract][Full Text] [Related]
6. The role of fenofibrate in clinical practice.
Zambon A; Cusi K
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
[TBL] [Abstract][Full Text] [Related]
7. Medical management of diabetic retinopathy: an overview.
Malek M; Khamseh ME; Aghili R; Emami Z; Najafi L; Baradaran HR
Arch Iran Med; 2012 Oct; 15(10):635-40. PubMed ID: 23020540
[TBL] [Abstract][Full Text] [Related]
8. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
9. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
Pérez A
Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585
[No Abstract] [Full Text] [Related]
10. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate.
Sacks FM
Am J Cardiol; 2008 Dec; 102(12A):34L-40L. PubMed ID: 19084088
[TBL] [Abstract][Full Text] [Related]
11. Prevention and treatment of diabetic retinopathy: evidence from large, randomized trials. The emerging role of fenofibrate.
Simó R; Hernández C
Rev Recent Clin Trials; 2012 Feb; 7(1):71-80. PubMed ID: 21864248
[TBL] [Abstract][Full Text] [Related]
12. Fenofibrate and Diabetic Retinopathy.
Knickelbein JE; Abbott AB; Chew EY
Curr Diab Rep; 2016 Oct; 16(10):90. PubMed ID: 27525681
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus.
Wanner C; Krane V
Kidney Blood Press Res; 2011; 34(4):209-17. PubMed ID: 21691123
[TBL] [Abstract][Full Text] [Related]
14. Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies.
Wright AD; Dodson PM
Eye (Lond); 2011 Jul; 25(7):843-9. PubMed ID: 21436845
[TBL] [Abstract][Full Text] [Related]
15. Fenofibrate and diabetic retinopathy.
Firth J
Lancet; 2008 Mar; 371(9614):722; author reply 722. PubMed ID: 18313496
[No Abstract] [Full Text] [Related]
16. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
Wierzbicki AS
Diabetes Obes Metab; 2009 Mar; 11(3):261-70. PubMed ID: 17645560
[TBL] [Abstract][Full Text] [Related]
17. [Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study].
Ai M; Yoshida M
Nihon Rinsho; 2010 Nov; 68 Suppl 9():285-90. PubMed ID: 21661165
[No Abstract] [Full Text] [Related]
18. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
Steinmetz A
Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
[TBL] [Abstract][Full Text] [Related]
19. Retinopathy progression in type 2 diabetes.
Baum SJ
N Engl J Med; 2010 Nov; 363(22):2172; author reply 2173-4. PubMed ID: 21105808
[No Abstract] [Full Text] [Related]
20. Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group
Diabetes Care; 2016 Jul; 39(7):1089-100. PubMed ID: 27289122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
